Document Detail


Ertapenem clearance during modeled continuous renal replacement therapy.
MedLine Citation:
PMID:  19115194     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To determine ertapenem transmembrane clearance (CLtm) during continuous renal replacement therapy (CRRT) using a validated in vitro model. METHODS: Ertapenem clearance during continuous hemofiltration and hemodialysis was assessed with AN69 and polysulfone hemodiafilters at 4 dialysate (Qd) and ultrafiltration rates (Quf): 1, 2, 3, and 6 l/hour. Blood and dialysate samples were collected at each flow rate and assayed for urea (control solute) and ertapenem concentrations. The experiment was repeated 5 times for each hemodiafilter type. Ertapenem and urea sieving coefficient (SC) and saturation coefficient (SA) were assessed, and CLtm calculated. RESULTS: In continuous hemofiltration mode, urea and ertapenem SC ranged from 1.00 to 1.19 at all Quf and did not differ between hemodiafilter types. Consequently, convective CLtm also did not differ between hemodiafilters. In continuous dialysis mode, urea Cltm did not differ between hemodiafilter types at any Qd. However, ertapenem SA and CLtm were significantly different between hemodiafilter types at Qd 6l/hour (p<0.001). As Qd increased, mean +/- SD AN69 SA declined significantly from 0.87 +/- 0.12 at Qd 1 l/hour to 0.45 +/- 0.02 at Qd 6 l/hour (p<0.001). Ertapenem SA did not differ at any Qd with the polysulfone hemodiafilter (range 0.71-0.80). CONCLUSION: Ertapenem was cleared substantially in these in vitro CRRT models. However, our findings illustrate discordance between our observed SC and SA and the published unbound fraction of ertapenem. This finding has been reported with many other drugs, including carbapenem antibiotics. If in vivo studies corroborate our SA and SC findings, dosage adjustment for patients receiving CRRT will be required.
Authors:
J M Stevenson; J H Patel; M D Churchwell; A M Vilay; D D Depestel; F Sörgel; M Kinzig; V Jakob; B A Mueller
Related Documents :
11326624 - Chiari i malformation: clinical presentation and management.
11504644 - Stereoselective detoxification of chiral sarin and soman analogues by phosphotriesterase.
17620344 - Interactions between human ugt1a1, ugt1a4, and ugt1a6 affect their enzymatic activities.
18643254 - Spiral trajectory in the horizontal brazil nut effect.
12898264 - Impact of menstrual cycle phase on the exercise status of young, sedentary women.
10701124 - Characterization of university-level introductory genetics courses in canada.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The International journal of artificial organs     Volume:  31     ISSN:  0391-3988     ISO Abbreviation:  Int J Artif Organs     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-30     Completed Date:  2009-03-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802649     Medline TA:  Int J Artif Organs     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1027-34     Citation Subset:  IM    
Affiliation:
Department of Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Bacterial Agents / pharmacokinetics*
Dialysis Solutions / chemistry
Hemofiltration*
Kidney Failure / metabolism*,  therapy
Membranes, Artificial
Metabolic Clearance Rate
Models, Biological
Renal Dialysis*
Swine
beta-Lactams / pharmacokinetics*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Dialysis Solutions; 0/Membranes, Artificial; 0/beta-Lactams; 0/ertapenem

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gene delivery systems for gene therapy in tissue engineering and central nervous system applications...
Next Document:  Application of fuzzy logic to predicting erythropoietic response in hemodialysis patients.